ASX ANNOUNCEMENT

Lumos Expands FebriDx® Adoption Across WellStreet Urgent Care Locations

Key Highlights

- **Lumos expands FebriDx® adoption with the 6th largest urgent care network in the U.S., WellStreet Urgent Care, as testing rolls out to an additional 97 locations.**
- **Under WellStreet's protocol, FebriDx® will be offered to patients presenting with acute respiratory infection (ARI) symptoms, which WellStreet estimates account for 70–80% of patient visits during cold and flu season.**
- **The WellStreet urgent care network represents over 1 million acute respiratory presentations per annum.**
- **Continued expansion is anticipated to include all WellStreet locations (200+) in all markets by 31 December 2026.**
- **The expanded WellStreet rollout will bring the number of U.S. sites using FebriDx® to 365 upon implementation.**

MELBOURNE, Australia (9 November 2026) – Lumos Diagnostics Holdings Ltd (ASX: LDX, "Lumos" or the "Company"), a leader in rapid, point-of-care diagnostic technologies, today received confirmation that WellStreet Urgent Care ("WellStreet") will expand the standardized adoption of FebriDx® across its network of more than 200 urgent care locations.

FebriDx® is a rapid point-of-care test that uses a fingerstick blood sample to aid in the differentiation between bacterial and non-bacterial infection.

On 16 October 2025, Lumos announced that it had entered into a single site pilot agreement with WellStreet to advance testing and reimbursement pathways for FebriDx® through WellStreet's joint venture with Piedmont Healthcare in Atlanta, Georgia.

Following the success of the pilot program and subsequent to the U.S. Food and Drug Administration (U.S. FDA) granting CLIA waiver for FebriDx® on 27 March 2026, WellStreet and Lumos announced on 14 April 2026 that they would expand the program to an additional 43 locations within WellStreet's network of urgent care clinics in Michigan and Georgia.

Building on the success of the program, WellStreet has now elected to expand the standardized adoption of FebriDx® to a total of 141 locations across Ohio, Georgia and Michigan.

In addition, Lumos and WellStreet anticipate that expansion will continue and FebriDx® will be offered across all WellStreet locations (200+) in the near future.

Under a protocol implemented by WellStreet, FebriDx® will be offered to patients presenting with ARI symptoms. Test results will be available to the provider prior to entering the examination room, enabling faster clinical decision-making and more timely diagnosis and treatment of patients. WellStreet estimates that 70-80% of patient visits are related to acute respiratory infection during cold and flu season.

"FebriDx has become a valuable tool to our clinicians during this pilot period, augmenting their ability to appropriately diagnose and treat patients with acute respiratory illnesses. Along with patient and clinician satisfaction, we have seen measurable improvement in antibiotic stewardship that can be attributed to the introduction of this test in our centers. We are excited to expand access to FebriDx® testing and the associated benefits to our patients and the healthcare system at large in the coming weeks." **Brian S. Bobb, M.D., Senior Medical Officer – WellStreet Urgent Care**

"The decision by WellStreet, one of the leading urgent care operators in the U.S., to standardise FebriDx® within its triage protocols across additional locations is a strong endorsement of the product's clinical value. FebriDx® helps physicians make more informed, data-driven decisions at the point of care, supporting both improved patient management and responsible antibiotic stewardship." **Doug Ward, CEO - Lumos Diagnostics**

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics (ASX: LDX) specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

About WellStreet Urgent Care

WellStreet Urgent Care helps health systems expand access, reach more consumers and turn first-time urgent care visits into lasting patient relationships. By creating a scalable network that operates under the health system's brand and EMR, urgent care becomes a powerful front door to primary and specialty care. Combining clinical and operational expertise, its more than 200 urgent care centers boast best-in-class patient experience scores and better than average wait times, making them a valuable community resource for convenient, high-quality care. WellStreet is part of the less than 10% of urgent care providers nationwide to receive accreditation from the Urgent Care Association and proactively pursues quality and compliance excellence, rising above the standard for the urgent care industry.

For more information, visit WellStreet.com

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:
Haley Chartres – Australia
H^CK Director
haley@hck.digital
+61 423 139 163

Investor Contact:
George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:
Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598